research articles ncbi

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts

Research articles

A CRISPRi/a screening platform to study cellular nutrient transport in diverse microenvironments

Chidley et al. report a CRISPR interference/activation screening platform to systematically interrogate the contribution of nutrient transporters to support cancer cell proliferation in environments of variable composition.

• Christopher Chidley
• Alicia M. Darnell
• Peter K. Sorger

Transcription-coupled DNA–protein crosslink repair by CSB and CRL4 CSA -mediated degradation

Three studies identify a transcription-coupled DNA–protein crosslink repair pathway that depends on the Cockayne syndrome proteins and the proteasome.

• Marjolein van Sluis
• Jurgen A. Marteijn

Endogenous aldehyde-induced DNA–protein crosslinks are resolved by transcription-coupled repair

• Yasuyoshi Oka
• Yuka Nakazawa

Transcription-coupled repair of DNA–protein cross-links depends on CSA and CSB

Three studies identify a transcription-coupled DNA–protein cross-link repair pathway that depends on the Cockayne syndrome proteins and the proteasome.

• Christopher J. Carnie
• Aleida C. Acampora
• Julian Stingele

Fatty acyl-coenzyme A activates mitochondrial division through oligomerization of MiD49 and MiD51

Liu et al. find that long-chain acyl-coenzyme A activates two mitochondrial fission proteins, MiD49 and MiD51, by inducing their oligomerization. This activates their ability to stimulate DRP1 GTPase activity and triggers mitochondrial division.

• Frieda Kage
• Henry N. Higgs

CD32 captures committed haemogenic endothelial cells during human embryonic development

Scarfò, Randolph et al. perform transcriptomic analysis of 28- to 32-day human embryos and identify CD32 as a marker of haemogenic endothelial cells (HECs), thus providing a strategy to isolate HECs from human embryos and pluripotent stem cell cultures.

• Rebecca Scarfò
• Lauren N. Randolph
• Andrea Ditadi

A lipid atlas of human and mouse immune cells provides insights into ferroptosis susceptibility

Morgan, Pernes and colleagues perform mass spectrometry-based targeted lipidomics and provide a comprehensive lipid profile of human and mouse immune cells, which they then show confer differential ferroptosis susceptibilities.

• Pooranee K. Morgan
• Gerard Pernes
• Andrew J. Murphy

Transcription bodies regulate gene expression by sequestering CDK9

Ugolini et al. show that transcription bodies regulate gene expression during zygotic genome activation in zebrafish development by sequestering CDK9 to limit the transcription of genes away from transcription bodies.

• Martino Ugolini
• Maciej A. Kerlin
• Nadine L. Vastenhouw

Proliferation-driven mechanical compression induces signalling centre formation during mammalian organ development

Shroff and colleagues report that cell proliferation induces localized mechanical compression in the tissue, driving the formation of the main mouse tooth signalling centre via differential YAP expression.

• Neha Pincha Shroff
• Ophir D. Klein

Glucose controls lipolysis through Golgi PtdIns4P-mediated regulation of ATGL

Ding et al. find a mechanism coordinating fatty acid and glucose supply. Glucose-driven Golgi phosphatidylinositol 4-phosphate levels impact the assembly of E3 ligase complex CUL7–FBXW8, controlling adipose triglyceride lipase levels and lipolysis.

• Lianggong Ding
• Florian Huwyler
• Christian Wolfrum

Cyclophilin A supports translation of intrinsically disordered proteins and affects haematopoietic stem cell ageing

Maneix, Iakova and colleagues report that cyclophilin A is a chaperone for, and regulator of, intrinsically disordered proteins within haematopoietic stem and progenitor cells, with potential effects on ageing-like phenotypes and lineage commitment.

• Laure Maneix
• Polina Iakova
• André Catic

Disordered C-terminal domain drives spatiotemporal confinement of RNAPII to enhance search for chromatin targets

Using single-molecule tracking and spatiotemporal mapping, Ling et al. show that the C-terminal domain of RNA polymerase II facilitates its dynamic confinement in subnuclear regions enriched in active genes, where it promotes targeted transcription.

• Yick Hin Ling

A cell fate decision map reveals abundant direct neurogenesis bypassing intermediate progenitors in the human developing neocortex

Coquand, Brunet Avalos et al. develop an imaging method to map basal radial glial cell division in human fetal tissue and cerebral organoids and detect abundant symmetric amplifying, but also direct neurogenic divisions bypassing intermediate progenitors.

• Laure Coquand
• Clarisse Brunet Avalos
• Alexandre D. Baffet

A palmitoylation–depalmitoylation relay spatiotemporally controls GSDMD activation in pyroptosis

Xu and colleagues identify a sequential palmitoylation–depalmitoylation mechanism that controls GSDMD cleavage by caspases, plasma membrane trafficking and oligomerization, thereby triggering pyroptosis in a spatial and temporal manner.

Defective prelamin A processing promotes unconventional necroptosis driven by nuclear RIPK1

Yang, Zhang et al. identify a non-canonical form of necroptosis driven by nuclear RIPK1-mediated nuclear membrane rupture as a result of ZMPSTE24 deficiency and defective prelamin A processing commonly observed in progeroid disorders.

• Yuanxin Yang

ACE2-dependent and -independent SARS-CoV-2 entries dictate viral replication and inflammatory response during infection

Duan et al. show that ACE2-dependent and ACE2-independent entry of SARS-COV-2 in epithelial cells versus myeloid cells differentially regulates viral replication and inflammatory responses, thereby contributing to COVID-19 progression and pathology.

• Tianhao Duan
• Changsheng Xing
• Rong-Fu Wang

Competence for neural crest induction is controlled by hydrostatic pressure through Yap

Alasaadi et al. report the role of hydrostatic pressure in regulating embryonic competence in the developing neural crest.

• Delan N. Alasaadi
• Lucas Alvizi
• Roberto Mayor

Loss of WIPI4 in neurodegeneration causes autophagy-independent ferroptosis

Zhu et al. show that loss of WIPI4, as seen in β-propeller protein-associated neurodegeneration, causes ferroptosis independently of autophagy due to an imbalance in phosphatidylethanolamine levels.

• Motoki Fujimaki
• David C. Rubinsztein

Distinct pathways drive anterior hypoblast specification in the implanting human embryo

Weatherbee, Weberling, Gantner et al. find contrasting requirements for BMP in the anterior signalling centre and pre-implantation epiblast between mice and humans. They further find that NOTCH may be indispensable for human epiblast survival.

• Bailey A. T. Weatherbee
• Antonia Weberling
• Magdalena Zernicka-Goetz

Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2–SP1–SAT1 axis

Murthy et al. demonstrate that cancer-associated fibroblast-derived acetate regulates polyamine homeostasis via an ACSS2–SP1–SAT1 axis in pancreatic cancer cells, thus enabling cell survival and tumour development under acidosis.

• Divya Murthy
• Kuldeep S. Attri
• Pankaj K. Singh

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

An official website of the United States government

Here’s how you know

Official websites use .gov A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Biomedical Literature | Biomedical Topics | Health Services and Public Health | Intramural Research |  History of Medicine | Policies and Guidelines

Biomedical Literature

• Biomedical journal literature. See MEDLINE/PubMed Resources for more information. Learn how to find full text articles  in PubMed.
• A digital archive of life sciences journal literature.
• LocatorPlus is the Library's online catalog containing catalog records for books, audiovisuals, journals, computer files, and other materials in the Library's collections.
• Electronic Databases & Directories: Alphabetical List and Subject List

Biomedical Topics

Computational molecular biology.

• A tool that finds regions of similarity between biological sequences. The program compares nucleotide or protein sequences to sequence databases and calculates the statistical significance.
• A database of nucleotide sequences.
• A database of macromolecular 3D structures, as well as tools for their visualization and comparative analysis.
• A database of taxonomic names of lineages of organisms represented in NCBI's sequence databases.
• A database to identify the conserved domains present in a protein sequence.
• A collection of reference sequences for genomes, gene transcripts, and proteins.
• A computer algorithm developed at NCBI and used to identify similar protein 3-dimensional structures ("similar structures") by purely geometric criteria and to identify distant homologs that cannot be recognized by sequence comparison.

Health Data Standards and Natural Language Processing

• Clinical vocabulary standards and tools that support implementation of Meaningful Use, C-CDA, and other programs

Human Genome Resources

• A guide to genes and inherited disorders.
• Gene integrates information from a wide range of species. A record may include nomenclature, Reference Sequences (RefSeqs), maps, pathways, variations, phenotypes, and links to genome-, phenotype-, and locus-specific resources worldwide.
• A genome browser supporting the exploration and analysis of more than 580 eukaryotic RefSeq genome assemblies.
• More Human Genome resources at NCBI
• Health Services Research and Public Health

Intramural Research

• NLM Intramural Research Program

History of Medicine

• Research Tools
• Historical Collections
• Exhibition Program
• Historical Collections Copyright Information

Policies and Guidelines

• NIH Public Access Compliance Toolkit
• Research Reporting Guidelines and Initiatives: By Organization
• Citing Medicine: the NLM Style Guide for Authors, Editors, and Publishers
• NLM Web Policies (Privacy and Security ; NLM Social Media Comments Policy ; Copyright)
• Patron Guide to Copyright and Historical Materials

Resources For You

• For Health Care Professionals
• For Librarians
• For the Public
• For Publishers
• Training and Careers

Last Reviewed: February 22, 2024

PMC International

PMC International (PMCI) is a collaborative effort between: NIH / NLM; publishers and U.S. funding agencies that contribute content to the PMC archive; and funding organizations in other parts of the world that also wish to preserve and provide free access to journal articles authored by the researchers they support.

The collaboration helps funding organizations build national or regional repositories of funded research articles, which they may supplement with other materials of particular interest to their respective communities. It also makes possible the exchange of journal articles between repositories in the PMCI network, subject to copyright and related permissions.

The PMCI network currently comprises (U.S. / NLM) PMC and Europe PMC. NLM’s collaboration with Europe PMC is based on a formal agreement between NLM and Europe PMC's sponsors concerning the management of any content the center gets from PMC. The agreement protects the rights of those who deposited the content in PMC, and ensures the integrity of that content by requiring each center to use NCBI's pPMC software, described below.

Europe PubMed Central (Europe PMC) is an outgrowth and expansion of UKPMC, which was first launched in January 2007 with sponsorship from the Wellcome Trust and several other funders of biomedical research in the UK. With the addition of other European funders, including the European Research Council, UKPMC was renamed Europe PMC in November 2012. Europe PMC receives all of its final published articles directly from U.S. PMC. It also accepts and processes author manuscripts of journal articles funded by the Europe PMC sponsoring agencies and makes them available to U.S. PMC and the Author Manuscript Dataset .

Status Update:

PubMed Central Canada (PMC Canada) ceased operations on February 23, 2018. Details of this decision are available on the PMC Canada website [Internet Archive].

PMC Canada content will remain in the PMC archive and continue to be publicly searchable through PMC (US) and Europe PMC.

PMC Canada [Internet Archive], was operational from October 2009 to February 2018. PMC Canada represented a partnership between the Canadian Institutes of Health Research (CIHR), the National Research Council Canada’s National Science Library (NRC-NSL), and the NLM. PMC Canada content remains available in the PMC archive and continues to be publicly searchable through PMC (US) and Europe PMC.

Content Available in Europe PMC

Europe PMC includes almost all PMC content, the sole exception being final published articles from publishers who have not given permission for their content to be shared with one or both of these repositories. Since July 2006, all PMC Participation Agreements have included permission to make a participating journal's PMC content available to Europe PMC (formerly UKPMC) automatically. Publishers participating in PMC prior to July 2006 were asked for permission to deposit their content into UKPMC, and most agreed to it.

Future PMCI Centers

NLM will consider expanding the PMCI network to include a center serving other countries or regions, if the following conditions are met:

The need for a new center must be based on there being one or more research funding organizations in the region with public or open access policies that require the deposit of funded research papers in a PMC-like repository. There must be solid evidence that these policies, and the way in which they are implemented, will contribute a sufficient volume of papers on a continuing basis to justify the investment in a new center.

The new center must be sponsored and managed by a national or international agency with a commitment to building and managing the archive for perpetuity. It may be a government agency, or a not-for-profit organization at an equivalent national or international level, formed by non-commercial entities such as funding agencies and research institutions.

The new center must attain an operational level that meets standards defined by NLM, and must sign an agreement with NLM concerning the management of the archive.

If NLM agrees to support a new PMCI center, the center will be able to include in its repository all of the material in the PMC Open Access subset , as well as the Author Manuscripts in PMC from NIH and other research funders. NLM does not plan to ask other PMC participating publishers for permission to redistribute their content as it did for the first two PMCI centers.

Portable PMC (pPMC)

Portable PMC (pPMC) is a software package developed by NLM's National Center for Biotechnology Information (NCBI). It is derived from the software used to operate the U.S. PMC system at NLM. It allows PMCI centers to import data from PMC, build a local database, and display the content of each article in the PMC style. The pPMC software itself does not include any rights to the PMC content.

Last modified: Wed June 28 2023

Advertisement

Supported by

Complications From Alcohol Use Are Rising Among Women

New research shows that alcohol-related liver disease and other health problems increased even more than expected among women ages 40 to 64 during the pandemic.

• Share full article

By Dani Blum

A new study adds to a mounting body of evidence showing that rising alcohol consumption among women is leading to higher rates of death and disease. The report, published Friday in the journal JAMA Health Forum , examined insurance claims data from 2017 to 2021 on more than 14 million Americans ages 15 and older. Researchers found that during the first year and a half of the coronavirus pandemic, women ages 40 to 64 were significantly more likely than expected to experience serious complications like alcohol-related cardiovascular and liver disease, as well as severe withdrawal.

The Background

Alcohol consumption in the United States has generally increased over the last 20 years , said Dr. Timothy Naimi, the director of the Canadian Institute for Substance Use Research at the University of Victoria. Dr. Naimi was a co-author on a recent paper that showed deaths from excessive alcohol use in the United States rose by nearly 30 percent between 2016 and 2021.

While men still die more often from drinking-related causes than women, deaths among women are climbing at a faster rate. “The gap is narrowing,” said Dr. Bryant Shuey, an assistant professor of medicine at the University of Pittsburgh and the lead author of the new study.

The Research

The study looked at serious health issues related to drinking, including alcohol-related liver and heart disease, inflammation of the stomach lining that led to bleeding, pancreatitis, alcohol-related mood disorders and withdrawal. Researchers compared insurance claims data for these complications with the rates they expected to see based on past prevalence of these conditions.

In nearly every month from April 2020 to September 2021, women ages 40 to 64 experienced complications from alcohol-related liver disease — a range of conditions that can develop when fat begins to accumulate in the liver — at higher rates than researchers predicted. If damage from drinking continues, scar tissue builds up in the liver and leads to a later stage of the disease, called cirrhosis. Some people with alcohol-related liver disease also develop severe liver inflammation, known as alcohol-associated hepatitis.

Rates of alcohol-related complications during the pandemic were also higher than predicted among men ages 40 to 64, but those increases were not statistically significant. But “men are not out of the woods” and still face health risks, Dr. Shuey said.

The Limitations

The study examined data only up until September 2021. Katherine Keyes, a professor of epidemiology at Columbia University who was not involved in the latest study, said she expected that alcohol use might keep rising among women — a pattern that could contribute to even more health issues.

And since the study relied on insurance claims, Dr. Shuey said it told an incomplete story. If someone is treated in the emergency room for an inflamed pancreas but doesn’t disclose a drinking history, for example, that instance may not be registered as an alcohol-related complication.

“The truth is, we’re probably underestimating this,” he said.

The Takeaways

These findings underscore how patterns of heavy drinking can translate into serious health consequences. Over the last 10 years, a growing number of American women — and particularly women in middle age — have reported binge-drinking, Dr. Keyes said.

“It used to be that 18- to 25-year-old males were the most likely to drink or the most likely to binge,” said Aaron White, a neuroscientist at the National Institute on Alcohol Abuse and Alcoholism. Now, binge drinking occurs more among people between the ages of 26 to 34, and is becoming more common among women. “Everything’s just getting pushed back later,” he said.

Demographic shifts can also help explain why women are drinking at higher rates, Dr. Keyes said. Women tend to marry and have children at later ages than in previous decades, so they spend more time in what Dr. Keyes calls a “high-risk period for heavy drinking.”

“People don’t realize the real health consequences these heavy drinking patterns can have,” she added.

These consequences take time to develop and often emerge between ages 40 and 60. Complications can occur after “years of heavy, persistent alcohol use,” Dr. Shuey said.

These longer-term increases in drinking predate the pandemic and might have increased the risk of health problems among women before Covid-19 hit. But higher levels of drinking during lockdowns may have exacerbated these issues or contributed to new complications, especially as women bore the brunt of family responsibilities, Dr. White said.

Even as research mounts on the harms of alcohol, many people might struggle to change their habits, Dr. White said.

“If you’ve been drinking wine with dinner every night for the last 20 years, just seeing a headline is not going to be enough to make you throw your wine away,” he said. “I think it’s going to be a slow cultural shift.”

Dani Blum is a health reporter for The Times. More about Dani Blum

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• Springer Nature - PMC COVID-19 Collection

A Review of Coronavirus Disease-2019 (COVID-19)

Tanu singhal.

Department of Pediatrics and Infectious Disease, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India

There is a new public health crises threatening the world with the emergence and spread of 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus originated in bats and was transmitted to humans through yet unknown intermediary animals in Wuhan, Hubei province, China in December 2019. There have been around 96,000 reported cases of coronavirus disease 2019 (COVID-2019) and 3300 reported deaths to date (05/03/2020). The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction. Many people are asymptomatic. The case fatality rate is estimated to range from 2 to 3%. Diagnosis is by demonstration of the virus in respiratory secretions by special molecular tests. Common laboratory findings include normal/ low white cell counts with elevated C-reactive protein (CRP). The computerized tomographic chest scan is usually abnormal even in those with no symptoms or mild disease. Treatment is essentially supportive; role of antiviral agents is yet to be established. Prevention entails home isolation of suspected cases and those with mild illnesses and strict infection control measures at hospitals that include contact and droplet precautions. The virus spreads faster than its two ancestors the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), but has lower fatality. The global impact of this new epidemic is yet uncertain.

Introduction

The 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) as it is now called, is rapidly spreading from its origin in Wuhan City of Hubei Province of China to the rest of the world [ 1 ]. Till 05/03/2020 around 96,000 cases of coronavirus disease 2019 (COVID-19) and 3300 deaths have been reported [ 2 ]. India has reported 29 cases till date. Fortunately so far, children have been infrequently affected with no deaths. But the future course of this virus is unknown. This article gives a bird’s eye view about this new virus. Since knowledge about this virus is rapidly evolving, readers are urged to update themselves regularly.

Coronaviruses are enveloped positive sense RNA viruses ranging from 60 nm to 140 nm in diameter with spike like projections on its surface giving it a crown like appearance under the electron microscope; hence the name coronavirus [ 3 ]. Four corona viruses namely HKU1, NL63, 229E and OC43 have been in circulation in humans, and generally cause mild respiratory disease.

There have been two events in the past two decades wherein crossover of animal betacorona viruses to humans has resulted in severe disease. The first such instance was in 2002–2003 when a new coronavirus of the β genera and with origin in bats crossed over to humans via the intermediary host of palm civet cats in the Guangdong province of China. This virus, designated as severe acute respiratory syndrome coronavirus affected 8422 people mostly in China and Hong Kong and caused 916 deaths (mortality rate 11%) before being contained [ 4 ]. Almost a decade later in 2012, the Middle East respiratory syndrome coronavirus (MERS-CoV), also of bat origin, emerged in Saudi Arabia with dromedary camels as the intermediate host and affected 2494 people and caused 858 deaths (fatality rate 34%) [ 5 ].

Origin and Spread of COVID-19 [ 1 , 2 , 6 ]

In December 2019, adults in Wuhan, capital city of Hubei province and a major transportation hub of China started presenting to local hospitals with severe pneumonia of unknown cause. Many of the initial cases had a common exposure to the Huanan wholesale seafood market that also traded live animals. The surveillance system (put into place after the SARS outbreak) was activated and respiratory samples of patients were sent to reference labs for etiologic investigations. On December 31st 2019, China notified the outbreak to the World Health Organization and on 1st January the Huanan sea food market was closed. On 7th January the virus was identified as a coronavirus that had >95% homology with the bat coronavirus and > 70% similarity with the SARS- CoV. Environmental samples from the Huanan sea food market also tested positive, signifying that the virus originated from there [ 7 ]. The number of cases started increasing exponentially, some of which did not have exposure to the live animal market, suggestive of the fact that human-to-human transmission was occurring [ 8 ]. The first fatal case was reported on 11th Jan 2020. The massive migration of Chinese during the Chinese New Year fuelled the epidemic. Cases in other provinces of China, other countries (Thailand, Japan and South Korea in quick succession) were reported in people who were returning from Wuhan. Transmission to healthcare workers caring for patients was described on 20th Jan, 2020. By 23rd January, the 11 million population of Wuhan was placed under lock down with restrictions of entry and exit from the region. Soon this lock down was extended to other cities of Hubei province. Cases of COVID-19 in countries outside China were reported in those with no history of travel to China suggesting that local human-to-human transmission was occurring in these countries [ 9 ]. Airports in different countries including India put in screening mechanisms to detect symptomatic people returning from China and placed them in isolation and testing them for COVID-19. Soon it was apparent that the infection could be transmitted from asymptomatic people and also before onset of symptoms. Therefore, countries including India who evacuated their citizens from Wuhan through special flights or had travellers returning from China, placed all people symptomatic or otherwise in isolation for 14 d and tested them for the virus.

Cases continued to increase exponentially and modelling studies reported an epidemic doubling time of 1.8 d [ 10 ]. In fact on the 12th of February, China changed its definition of confirmed cases to include patients with negative/ pending molecular tests but with clinical, radiologic and epidemiologic features of COVID-19 leading to an increase in cases by 15,000 in a single day [ 6 ]. As of 05/03/2020 96,000 cases worldwide (80,000 in China) and 87 other countries and 1 international conveyance (696, in the cruise ship Diamond Princess parked off the coast of Japan) have been reported [ 2 ]. It is important to note that while the number of new cases has reduced in China lately, they have increased exponentially in other countries including South Korea, Italy and Iran. Of those infected, 20% are in critical condition, 25% have recovered, and 3310 (3013 in China and 297 in other countries) have died [ 2 ]. India, which had reported only 3 cases till 2/3/2020, has also seen a sudden spurt in cases. By 5/3/2020, 29 cases had been reported; mostly in Delhi, Jaipur and Agra in Italian tourists and their contacts. One case was reported in an Indian who traveled back from Vienna and exposed a large number of school children in a birthday party at a city hotel. Many of the contacts of these cases have been quarantined.

These numbers are possibly an underestimate of the infected and dead due to limitations of surveillance and testing. Though the SARS-CoV-2 originated from bats, the intermediary animal through which it crossed over to humans is uncertain. Pangolins and snakes are the current suspects.

Epidemiology and Pathogenesis [ 10 , 11 ]

All ages are susceptible. Infection is transmitted through large droplets generated during coughing and sneezing by symptomatic patients but can also occur from asymptomatic people and before onset of symptoms [ 9 ]. Studies have shown higher viral loads in the nasal cavity as compared to the throat with no difference in viral burden between symptomatic and asymptomatic people [ 12 ]. Patients can be infectious for as long as the symptoms last and even on clinical recovery. Some people may act as super spreaders; a UK citizen who attended a conference in Singapore infected 11 other people while staying in a resort in the French Alps and upon return to the UK [ 6 ]. These infected droplets can spread 1–2 m and deposit on surfaces. The virus can remain viable on surfaces for days in favourable atmospheric conditions but are destroyed in less than a minute by common disinfectants like sodium hypochlorite, hydrogen peroxide etc. [ 13 ]. Infection is acquired either by inhalation of these droplets or touching surfaces contaminated by them and then touching the nose, mouth and eyes. The virus is also present in the stool and contamination of the water supply and subsequent transmission via aerosolization/feco oral route is also hypothesized [ 6 ]. As per current information, transplacental transmission from pregnant women to their fetus has not been described [ 14 ]. However, neonatal disease due to post natal transmission is described [ 14 ]. The incubation period varies from 2 to 14 d [median 5 d]. Studies have identified angiotensin receptor 2 (ACE 2 ) as the receptor through which the virus enters the respiratory mucosa [ 11 ].

The basic case reproduction rate (BCR) is estimated to range from 2 to 6.47 in various modelling studies [ 11 ]. In comparison, the BCR of SARS was 2 and 1.3 for pandemic flu H1N1 2009 [ 2 ].

Clinical Features [ 8 , 15 – 18 ]

The clinical features of COVID-19 are varied, ranging from asymptomatic state to acute respiratory distress syndrome and multi organ dysfunction. The common clinical features include fever (not in all), cough, sore throat, headache, fatigue, headache, myalgia and breathlessness. Conjunctivitis has also been described. Thus, they are indistinguishable from other respiratory infections. In a subset of patients, by the end of the first week the disease can progress to pneumonia, respiratory failure and death. This progression is associated with extreme rise in inflammatory cytokines including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNFα [ 15 ]. The median time from onset of symptoms to dyspnea was 5 d, hospitalization 7 d and acute respiratory distress syndrome (ARDS) 8 d. The need for intensive care admission was in 25–30% of affected patients in published series. Complications witnessed included acute lung injury, ARDS, shock and acute kidney injury. Recovery started in the 2nd or 3rd wk. The median duration of hospital stay in those who recovered was 10 d. Adverse outcomes and death are more common in the elderly and those with underlying co-morbidities (50–75% of fatal cases). Fatality rate in hospitalized adult patients ranged from 4 to 11%. The overall case fatality rate is estimated to range between 2 and 3% [ 2 ].

Interestingly, disease in patients outside Hubei province has been reported to be milder than those from Wuhan [ 17 ]. Similarly, the severity and case fatality rate in patients outside China has been reported to be milder [ 6 ]. This may either be due to selection bias wherein the cases reporting from Wuhan included only the severe cases or due to predisposition of the Asian population to the virus due to higher expression of ACE 2 receptors on the respiratory mucosa [ 11 ].

Disease in neonates, infants and children has been also reported to be significantly milder than their adult counterparts. In a series of 34 children admitted to a hospital in Shenzhen, China between January 19th and February 7th, there were 14 males and 20 females. The median age was 8 y 11 mo and in 28 children the infection was linked to a family member and 26 children had history of travel/residence to Hubei province in China. All the patients were either asymptomatic (9%) or had mild disease. No severe or critical cases were seen. The most common symptoms were fever (50%) and cough (38%). All patients recovered with symptomatic therapy and there were no deaths. One case of severe pneumonia and multiorgan dysfunction in a child has also been reported [ 19 ]. Similarly the neonatal cases that have been reported have been mild [ 20 ].

Diagnosis [ 21 ]

A suspect case is defined as one with fever, sore throat and cough who has history of travel to China or other areas of persistent local transmission or contact with patients with similar travel history or those with confirmed COVID-19 infection. However cases may be asymptomatic or even without fever. A confirmed case is a suspect case with a positive molecular test.

Specific diagnosis is by specific molecular tests on respiratory samples (throat swab/ nasopharyngeal swab/ sputum/ endotracheal aspirates and bronchoalveolar lavage). Virus may also be detected in the stool and in severe cases, the blood. It must be remembered that the multiplex PCR panels currently available do not include the COVID-19. Commercial tests are also not available at present. In a suspect case in India, the appropriate sample has to be sent to designated reference labs in India or the National Institute of Virology in Pune. As the epidemic progresses, commercial tests will become available.

Other laboratory investigations are usually non specific. The white cell count is usually normal or low. There may be lymphopenia; a lymphocyte count <1000 has been associated with severe disease. The platelet count is usually normal or mildly low. The CRP and ESR are generally elevated but procalcitonin levels are usually normal. A high procalcitonin level may indicate a bacterial co-infection. The ALT/AST, prothrombin time, creatinine, D-dimer, CPK and LDH may be elevated and high levels are associated with severe disease.

The chest X-ray (CXR) usually shows bilateral infiltrates but may be normal in early disease. The CT is more sensitive and specific. CT imaging generally shows infiltrates, ground glass opacities and sub segmental consolidation. It is also abnormal in asymptomatic patients/ patients with no clinical evidence of lower respiratory tract involvement. In fact, abnormal CT scans have been used to diagnose COVID-19 in suspect cases with negative molecular diagnosis; many of these patients had positive molecular tests on repeat testing [ 22 ].

Differential Diagnosis [ 21 ]

The differential diagnosis includes all types of respiratory viral infections [influenza, parainfluenza, respiratory syncytial virus (RSV), adenovirus, human metapneumovirus, non COVID-19 coronavirus], atypical organisms (mycoplasma, chlamydia) and bacterial infections. It is not possible to differentiate COVID-19 from these infections clinically or through routine lab tests. Therefore travel history becomes important. However, as the epidemic spreads, the travel history will become irrelevant.

Treatment [ 21 , 23 ]

Treatment is essentially supportive and symptomatic.

The first step is to ensure adequate isolation (discussed later) to prevent transmission to other contacts, patients and healthcare workers. Mild illness should be managed at home with counseling about danger signs. The usual principles are maintaining hydration and nutrition and controlling fever and cough. Routine use of antibiotics and antivirals such as oseltamivir should be avoided in confirmed cases. In hypoxic patients, provision of oxygen through nasal prongs, face mask, high flow nasal cannula (HFNC) or non-invasive ventilation is indicated. Mechanical ventilation and even extra corporeal membrane oxygen support may be needed. Renal replacement therapy may be needed in some. Antibiotics and antifungals are required if co-infections are suspected or proven. The role of corticosteroids is unproven; while current international consensus and WHO advocate against their use, Chinese guidelines do recommend short term therapy with low-to-moderate dose corticosteroids in COVID-19 ARDS [ 24 , 25 ]. Detailed guidelines for critical care management for COVID-19 have been published by the WHO [ 26 ]. There is, as of now, no approved treatment for COVID-19. Antiviral drugs such as ribavirin, lopinavir-ritonavir have been used based on the experience with SARS and MERS. In a historical control study in patients with SARS, patients treated with lopinavir-ritonavir with ribavirin had better outcomes as compared to those given ribavirin alone [ 15 ].

In the case series of 99 hospitalized patients with COVID-19 infection from Wuhan, oxygen was given to 76%, non-invasive ventilation in 13%, mechanical ventilation in 4%, extracorporeal membrane oxygenation (ECMO) in 3%, continuous renal replacement therapy (CRRT) in 9%, antibiotics in 71%, antifungals in 15%, glucocorticoids in 19% and intravenous immunoglobulin therapy in 27% [ 15 ]. Antiviral therapy consisting of oseltamivir, ganciclovir and lopinavir-ritonavir was given to 75% of the patients. The duration of non-invasive ventilation was 4–22 d [median 9 d] and mechanical ventilation for 3–20 d [median 17 d]. In the case series of children discussed earlier, all children recovered with basic treatment and did not need intensive care [ 17 ].

There is anecdotal experience with use of remdeswir, a broad spectrum anti RNA drug developed for Ebola in management of COVID-19 [ 27 ]. More evidence is needed before these drugs are recommended. Other drugs proposed for therapy are arbidol (an antiviral drug available in Russia and China), intravenous immunoglobulin, interferons, chloroquine and plasma of patients recovered from COVID-19 [ 21 , 28 , 29 ]. Additionally, recommendations about using traditional Chinese herbs find place in the Chinese guidelines [ 21 ].

Prevention [ 21 , 30 ]

Since at this time there are no approved treatments for this infection, prevention is crucial. Several properties of this virus make prevention difficult namely, non-specific features of the disease, the infectivity even before onset of symptoms in the incubation period, transmission from asymptomatic people, long incubation period, tropism for mucosal surfaces such as the conjunctiva, prolonged duration of the illness and transmission even after clinical recovery.

Isolation of confirmed or suspected cases with mild illness at home is recommended. The ventilation at home should be good with sunlight to allow for destruction of virus. Patients should be asked to wear a simple surgical mask and practice cough hygiene. Caregivers should be asked to wear a surgical mask when in the same room as patient and use hand hygiene every 15–20 min.

The greatest risk in COVID-19 is transmission to healthcare workers. In the SARS outbreak of 2002, 21% of those affected were healthcare workers [ 31 ]. Till date, almost 1500 healthcare workers in China have been infected with 6 deaths. The doctor who first warned about the virus has died too. It is important to protect healthcare workers to ensure continuity of care and to prevent transmission of infection to other patients. While COVID-19 transmits as a droplet pathogen and is placed in Category B of infectious agents (highly pathogenic H5N1 and SARS), by the China National Health Commission, infection control measures recommended are those for category A agents (cholera, plague). Patients should be placed in separate rooms or cohorted together. Negative pressure rooms are not generally needed. The rooms and surfaces and equipment should undergo regular decontamination preferably with sodium hypochlorite. Healthcare workers should be provided with fit tested N95 respirators and protective suits and goggles. Airborne transmission precautions should be taken during aerosol generating procedures such as intubation, suction and tracheostomies. All contacts including healthcare workers should be monitored for development of symptoms of COVID-19. Patients can be discharged from isolation once they are afebrile for atleast 3 d and have two consecutive negative molecular tests at 1 d sampling interval. This recommendation is different from pandemic flu where patients were asked to resume work/school once afebrile for 24 h or by day 7 of illness. Negative molecular tests were not a prerequisite for discharge.

At the community level, people should be asked to avoid crowded areas and postpone non-essential travel to places with ongoing transmission. They should be asked to practice cough hygiene by coughing in sleeve/ tissue rather than hands and practice hand hygiene frequently every 15–20 min. Patients with respiratory symptoms should be asked to use surgical masks. The use of mask by healthy people in public places has not shown to protect against respiratory viral infections and is currently not recommended by WHO. However, in China, the public has been asked to wear masks in public and especially in crowded places and large scale gatherings are prohibited (entertainment parks etc). China is also considering introducing legislation to prohibit selling and trading of wild animals [ 32 ].

The international response has been dramatic. Initially, there were massive travel restrictions to China and people returning from China/ evacuated from China are being evaluated for clinical symptoms, isolated and tested for COVID-19 for 2 wks even if asymptomatic. However, now with rapid world wide spread of the virus these travel restrictions have extended to other countries. Whether these efforts will lead to slowing of viral spread is not known.

A candidate vaccine is under development.

Practice Points from an Indian Perspective

At the time of writing this article, the risk of coronavirus in India is extremely low. But that may change in the next few weeks. Hence the following is recommended:

• Healthcare providers should take travel history of all patients with respiratory symptoms, and any international travel in the past 2 wks as well as contact with sick people who have travelled internationally.
• They should set up a system of triage of patients with respiratory illness in the outpatient department and give them a simple surgical mask to wear. They should use surgical masks themselves while examining such patients and practice hand hygiene frequently.
• Suspected cases should be referred to government designated centres for isolation and testing (in Mumbai, at this time, it is Kasturba hospital). Commercial kits for testing are not yet available in India.
• Patients admitted with severe pneumonia and acute respiratory distress syndrome should be evaluated for travel history and placed under contact and droplet isolation. Regular decontamination of surfaces should be done. They should be tested for etiology using multiplex PCR panels if logistics permit and if no pathogen is identified, refer the samples for testing for SARS-CoV-2.
• All clinicians should keep themselves updated about recent developments including global spread of the disease.
• Non-essential international travel should be avoided at this time.
• People should stop spreading myths and false information about the disease and try to allay panic and anxiety of the public.

Conclusions

This new virus outbreak has challenged the economic, medical and public health infrastructure of China and to some extent, of other countries especially, its neighbours. Time alone will tell how the virus will impact our lives here in India. More so, future outbreaks of viruses and pathogens of zoonotic origin are likely to continue. Therefore, apart from curbing this outbreak, efforts should be made to devise comprehensive measures to prevent future outbreaks of zoonotic origin.

Compliance with Ethical Standards

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Trending Articles

• A pan-cancer analysis of the microbiome in metastatic cancer. Battaglia TW, et al. Cell. 2024. PMID: 38599211
• Time-series reconstruction of the molecular architecture of human centriole assembly. Laporte MH, et al. Cell. 2024. PMID: 38604175
• ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion. Deng S, et al. Cell. 2024. PMID: 38614099
• Alectinib in Resected ALK -Positive Non-Small-Cell Lung Cancer. Wu YL, et al. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.
• How effective is digitalis in the treatment of congestive heart failure? Kimmelstiel C, et al. Am Heart J. 1988. PMID: 3051982 Review.

Latest Literature

• Am J Clin Nutr (1)
• Cancer Res (5)
• Crit Care Med (19)
• J Clin Invest (16)
• J Immunol (4)
• Nucleic Acids Res (3)
• Pediatrics (1)
• World J Gastroenterol (29)

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.